Predictors of tuberculosis treatment success under the DOTS program in Namibia

Expert Rev Respir Med. 2018 Nov;12(11):979-987. doi: 10.1080/17476348.2018.1520637. Epub 2018 Oct 4.

Abstract

Objectives: Optimal treatment success rates are critical to end tuberculosis in Namibia. Despite the scale-up of high quality directly observed therapy short-course strategy (DOTS) in Namibia, treatment success falls short of the global target of 90%. The objective of this study was to ascertain the predictors of treatment success rates under DOTS in Namibia to provide future direction.

Methods: A nation-wide comparative analysis of predictors of treatment success was undertaken. Tuberculosis cases in the electronic tuberculosis register were retrospectively reviewed over a 10-year period, 2004-2016. The patient, programmatic, clinical, and treatment predictors of treatment success were determined by multivariate logistic regression modeling using R software.

Results: 104,603 TB cases were registered at 300 DOTS sites in 37 districts. The 10-year period treatment success rate was 80%, and varied by region (77.2%-89.2%). The patient's sex and age were not significant predictors. The independent predictors for treatment success as were: Region of DOTS implementation (p=0.001), type of directly observed treatment (DOT) supporter (p<0.001), sputum conversion at 2 months (p=0.013), DOT regimen (p<0.001), cotrimoxazole prophylaxis (p=0.002), and HIV co-infection (p=0.001).

Conclusion: Targeted programmatic, clinical and treatment interventions are required to enhance DOTS treatment success in Namibia. These are now ongoing.

Keywords: DOTS program; TB; effectiveness; outcomes; predictors.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Antibiotic Prophylaxis
  • Antitubercular Agents / therapeutic use
  • Coinfection / epidemiology
  • Directly Observed Therapy*
  • Female
  • HIV Infections / epidemiology
  • Humans
  • Male
  • Namibia / epidemiology
  • Registries
  • Retrospective Studies
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Tuberculosis / drug therapy*
  • Tuberculosis / epidemiology*

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination